Perspective Therapeutics updates corporate presentation, highlights 212Pb pipeline and clinical progress

Perspective Therapeutics updated its corporate presentation highlighting progress across its 212Pb radiopharmaceutical portfolio and clinical data supporting advancement.Key Highlights:Original SEC Filing: Perspective Therapeutics, Inc. [ CATX ] - 8-K - Jul. 01, 2026This is an AI-powered summary. I…

Perspective Therapeutics updated its corporate presentation highlighting progress across its 212Pb radiopharmaceutical portfolio and clinical data supporting advancement.

Key Highlights:

Filed updated corporate presentation as Exhibit 99.1 to Form 8-K on July 1, 2026.
Emphasizes a 212Pb-based theranostic portfolio targeting solid tumors, including VMT-α-NET, VMT01, and PSV359.
Reports ongoing Phase 1/2a trials for VMT-α-NET (SSTR2+ NETs), VMT01 (melanoma) and PSV359 (FAP-α solid tumors).
Highlights clinical observations: durable disease control, deepening responses over time and preliminary anti-tumor activity at 3.0 mCi for VMT01.
Notes direct-to-hospital regional isotope production model, daily regional manufacturing to supply ready-to-administer product.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.